UNH
UnitedHealth Group Incorporated
UNH's fundamentals are mixed: free cash flow grew 31%, but earnings per share fell 8.5%. At 23x earnings, it's trading right at its usual valuation. Analysts expect strong earnings growth, though they disagree widely on how much.
VNRX
VolitionRx Limited
There isn't enough reported data to score VNRX yet.
UNH Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Stable | |
| Healthy | |
| Healthy |
UNH's cash flow and balance sheet are currently healthy, and its revenue and profitability are stable.
VNRX Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Under pressure | |
| Weak | |
| Unavailable |
VNRX's revenue is currently healthy, but its profitability and cash flow are under pressure. There isn't enough data to rate its balance sheet.
UNH PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 18x | $405 | — |
| Cheap | 19x | $325 | -20% |
| Fair | 23x | $410 | +1.2% |
| Current | 23x | $405 | — |
| Expensive | 30x | $526 | +30% |
Historical ranges are pointers, not guarantees.
UNH's PE is in its fair range at 23x. If earnings grow as analysts expect, today's price would be 18x next year's earnings, in its cheap range.
VNRX PE Valuation
VNRX has no meaningful PE right now: it lost money over the past year.
UNH Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Stable | |
| Improving | |
| Moderate | |
| Low |
Analysts expect UNH's earnings to grow and its profitability to improve, with its revenue holding steady. However, they disagree widely on these estimates.
VNRX Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Stable | |
| -- | |
| Limited | |
| Low |
Analysts expect VNRX's losses to shrink, with revenue holding steady. However, they disagree widely on these estimates.
UNH Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $22.65 | +29% |
| Q3 2026 | $17.55 | -8.5% |
| Q2 2026 | $15.58 | -33% |
| Q1 2026 | $13.28 | -44% |
| Q4 2025 | $13.23 | -15% |
| Q3 2025 | $19.17 | +25% |
| Q2 2025 | $23.09 | +53% |
| Q1 2025 | $23.89 | +46% |
| Q4 2024 | $15.51 | -35% |
UNH has the edge over VNRX on earnings quality, reporting a profit while its opponent remains loss making.
VNRX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$3.00 | +$1.81 |
| Q2 2026 | -$3.79 | +$1.27 |
| Q1 2026 | -$4.14 | +$1.24 |
| Q4 2025 | -$4.37 | +$1.83 |
| Q3 2022 | -$11.48 | -$2.48 |
| Q2 2022 | -$11.37 | -$3.17 |
| Q1 2022 | -$10.67 | -$2.07 |
| Q4 2021 | -$10.20 | -$1.20 |
VNRX is still losing money, but far less than before: $3.00 per share over the past year, against $11.48 at its worst in late 2022.
UNH Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $112.7B | -0.4% |
| Q2 2026 | $112B | +0.4% |
| Q1 2026 | $111.7B | +2% |
| Q4 2025 | $113.2B | +12% |
| Q3 2025 | $113.2B | +12% |
| Q2 2025 | $111.6B | +13% |
| Q1 2025 | $109.6B | +9.8% |
| Q4 2024 | $100.8B | +6.8% |
UNH's revenue has held roughly level: $113B last quarter, about level with the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 5.8% | +2 points |
| Q2 2026 | 7.1% | +2.5 points |
| Q1 2026 | 8.1% | -0.3 points |
| Q4 2025 | 0.3% | -7.4 points |
| Q3 2025 | 3.8% | -4.8 points |
| Q2 2025 | 4.6% | -3.4 points |
| Q1 2025 | 8.3% | +0.4 points |
| Q4 2024 | 7.7% | -0.4 points |
UNH has the edge over VNRX on profitability, with a higher operating margin.
VNRX Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $1.6M | +157% |
| Q2 2026 | $398.7K | -2% |
| Q1 2026 | $985.1K | +300% |
| Q4 2025 | $447K | +133% |
| Q3 2025 | $627.3K | +32% |
| Q2 2025 | $406.7K | +2.8% |
| Q1 2025 | $246.4K | +44% |
| Q4 2024 | $191.7K | -21% |
VNRX's revenue is growing: $2M last quarter, up 157% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -207% | +607 points |
| Q2 2026 | -1043% | +506 points |
| Q1 2026 | -543% | +1698 points |
| Q4 2025 | -1078% | +1939 points |
| Q3 2025 | -813% | +424 points |
| Q2 2025 | -1549% | +218 points |
| Q1 2025 | -2241% | +2647 points |
| Q4 2024 | -3017% | +566 points |
VNRX's operating margin was −207% last quarter, up 607 points from the same quarter a year ago, near the top of its range since 2020.
UNH Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $4.3B | -16% |
| Q2 2026 | $10.3B | +63% |
| Q1 2026 | $8.1B | +79% |
| Q4 2025 | $160M | -89% |
| Q3 2025 | $5.1B | -61% |
| Q2 2025 | $6.3B | +6.9% |
| Q1 2025 | $4.6B | +1037% |
| Q4 2024 | $1.5B | +$7.6B |
UNH has the edge over VNRX on cash generation, producing positive trailing cash flow while its opponent burns cash.
VNRX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$4.6M | -$1M |
| Q2 2026 | -$5.2M | +$1.2M |
| Q1 2026 | -$5.3M | -$989.5K |
| Q4 2025 | -$5.5M | +$1.5K |
| Q3 2025 | -$3.6M | +$1.9M |
| Q2 2025 | -$6.3M | +$431.9K |
| Q1 2025 | -$4.3M | +$4.1M |
| Q4 2024 | -$5.5M | -190% |
VNRX has burned cash in almost every quarter: −$21M over the past year, against −$20M the year before.
UNH Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.4% | -4M shares |
| 1 year | -0.7% | -6M shares |
| 3 years | -3.6% | -34M shares |
| 5 years | -5.5% | -53M shares |
| Available history | -6.6% | -64M shares |
UNH has the edge over VNRX on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $3.4B |
| Q2 2026 | $1.6B |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | $2.5B |
| Q1 2025 | $3B |
| Q4 2024 | $5B |
UNH spent $5B buying back its own shares over the past year, down 52% from the year before.
VNRX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +106% | +9.7M shares |
| 1 year | +249% | +13.5M shares |
| 3 years | +380% | +15M shares |
| 5 years | +611% | +16.2M shares |
| Available history | +865% | +16.9M shares |
VNRX has 19M diluted shares, up 249% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2024 | — |
| Q3 2024 | — |
| Q2 2024 | — |
| Q1 2024 | — |
| Q4 2023 | — |
| Q3 2023 | — |
| Q2 2023 | — |
| Q1 2023 | $31,772 |
UNH Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.7x | Healthy |
| Q2 2026 | 1.7x | Healthy |
| Q1 2026 | 2.2x | Moderate |
| Q4 2025 | 2.3x | Moderate |
| Q3 2025 | 1.7x | Healthy |
| Q2 2025 | 1.5x | Healthy |
| Q1 2025 | 1.3x | Healthy |
| Q4 2024 | 1.4x | Healthy |
UNH's net debt is about 1.7 years of its operating earnings (EBITDA), about the same as a year ago.
VNRX Net Leverage
VNRX's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
UNH Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 56.4 | Neutral |
| Stochastic | 60.0 | Neutral |
UNH's weekly RSI is 56 (neutral) and its Stochastic is 60 (neutral).
VNRX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 24.5 | Oversold |
| Stochastic | 4.8 | Oversold |
VNRX's weekly RSI is 24 (oversold) and its Stochastic is 5 (oversold).
UNH PE vs Healthcare Sector
| Metric | UNH | Sector median | Relative |
|---|---|---|---|
| PE | 23x | 26x | 11% below |
| PE % | 47 | 29 | 18 pts above |
UNH is trading at 23x earnings, a 11% discount to the Healthcare sector's median of 26x.
VNRX PE vs Healthcare Sector
VNRX has no meaningful PE right now: it lost money over the past year.
UNH Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $394.2 | 2.8% above |
| 20 week MA | $400.5 | 1.2% above |
| 50 week MA | $361.2 | 12% above |
| 100 week MA | $376.0 | 7.8% above |
| 200 week MA | $446.6 | 9.3% below |
UNH has the edge over VNRX on trend strength, trading above more of its moving averages.
VNRX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $0.20 | 10% below |
| 20 week MA | $0.52 | 65% below |
| 50 week MA | $2.51 | 93% below |
| 100 week MA | $7.06 | 97% below |
| 200 week MA | $14.3 | 99% below |
VNRX is in a downtrend: it's below all five of its weekly moving averages, and 99% below its 200-week average.
UNH Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $296.0 | $340.8 | +15% |
| 2021 | $340.8 | $495.4 | +45% |
| 2022 | $495.4 | $531.3 | +7.3% |
| 2023 | $531.3 | $526.5 | -0.9% |
| 2024 | $526.5 | $510.0 | -3.1% |
| 2025 | $510.0 | $331.8 | -35% |
| 2026 YTD | $331.8 | $405.1 | +22% |
UNH has the edge over VNRX on returns for 2026, with the stronger performance.
VNRX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $92.0 | $86.6 | -5.9% |
| 2021 | $86.6 | $64.8 | -25% |
| 2022 | $64.8 | $49.0 | -24% |
| 2023 | $49.0 | $14.3 | -71% |
| 2024 | $14.3 | $12.3 | -14% |
| 2025 | $12.3 | $5.00 | -59% |
| 2026 YTD | $5.00 | $0.18 | -96% |
VNRX has finished every year since 2020 lower, and it's down 96% so far in 2026.